Press Releases

Date Title and Summary Additional Formats
Toggle Summary Concert Pharmaceuticals Names Jesper Høiland to its Board of Directors
LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 29, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced today that Jesper Høiland has been appointed to its Board of Directors and will serve as a member of its Compensation Committee, effective immediately.
View HTML
Toggle Summary Concert Pharmaceuticals to Report First Quarter 2019 Financial Results on May 2, 2019
LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 25, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2019 financial results on Thursday, May 2, 2019 , before the U.S. financial markets open. The Company will host a conference call and webcast at
View HTML
Toggle Summary Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting
LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 11, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata will be presented in a poster presentation and a sponsored lecture at the 11 th Annual World Congress for
View HTML
Toggle Summary Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia
LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 10, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated an additional trial in the Phase 1 program evaluating CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for
View HTML
Toggle Summary Concert Pharmaceuticals Announces Decision from Patent Trial and Appeal Board in IPR Proceeding
LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 8, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a final written decision in connection with the inter partes review (IPR) of U.S.
View HTML
Toggle Summary Concert Pharmaceuticals to Present at Upcoming Oppenheimer Healthcare Conference
LEXINGTON, Mass. --(BUSINESS WIRE)--Mar. 12, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Oppenheimer 29 th Annual Healthcare Conference on March 19, 2019 at 1:00 p.m. ET in New York, NY .
View HTML
Toggle Summary Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata
LEXINGTON, Mass. --(BUSINESS WIRE)--Mar. 6, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.
View HTML
Toggle Summary Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata during Late-Breaker Session at American Academy of Dermatology Annual Meeting
Interim Data Analysis from 8 mg Twice-Daily Cohort of Investigational CTP-543 Showed Statistically Significant Effect on Primary Endpoint in Patients with Moderate-to-Severe Alopecia Areata LEXINGTON, Mass. --(BUSINESS WIRE)--Mar. 1, 2019-- Concert Pharmaceuticals, Inc.
View HTML
Toggle Summary Concert Pharmaceuticals Reports Year Ended 2018 Financial Results and Provides Update on Clinical Programs
Significant Clinical Progress in 2018; Multiple Trials with Milestones in 2019 Additional CTP-543 Phase 2 Data Expected Q3 2019 for Treatment of Alopecia Areata CTP-692 Poised to Advance into Phase 2 Development by Year End 2019 as Adjunctive Treatment for Schizophrenia Conference Call Scheduled
View HTML
Toggle Summary Concert Pharmaceuticals to Report Full Year 2018 Results on February 28, 2019
LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 21, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2018 , on Thursday, February 28, 2019 , before the U.S. financial markets open.
View HTML